Related content

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

By Crafter Claire   Vincent John P.   Tang Eric   Dudley Phillippa   James Neil H.   Klinowska Teresa   Davies Barry R.  

International Journal of Oncology, Vol. 47, Iss. 2, 2015-08 ,pp. : 446-454

Spandidos Publications

Access to resources Recommend Favorite

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma

By            

Oncology Reports, Vol. 27, Iss. 5, 2012-01 ,pp. : 1639-1645

Spandidos Publications

Access to resources Recommend Favorite

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

By              

Oncology Reports, Vol. 35, Iss. 2, 2016-01 ,pp. : 771-778

Spandidos Publications

Access to resources Recommend Favorite

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

By Maiello Monica   D’Alessio Amelia   Luca Antonella   Carotenuto Adele   Rachiglio Anna   Napolitano Maria   Cito Letizia   Guzzo Antonella   Normanno Nicola  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite